ЭТИОЛОГИЯ, ПАТОГЕНЕЗ И МЕТОДЫ ПРОФИЛАКТИКИ ВНЕЗАПНОЙ АРИТМИЧЕСКОЙ СМЕРТИ У БОЛЬНЫХ ИШЕМИЧЕСКОЙ БОЛЕЗНЬЮ СЕРДЦА
Аннотация
Хроническая сердечная недостаточность и ишемическая болезнь сердца остаются единственной наиболее частой причиной внезапной сердечной смерти (ВСС) в развитых странах. Внезапная сердечная смерть у больных с хронической сердечной недостаточностью составляет 50% всех случаев смерти от кардиоваскулярных причин. Желудочковые тахиаритмии в большинстве случаев являются причиной внезапной сердечной смерти, триггером которых является острая ишемия. В обзоре проводится литературный анализ об этиологии, патогенезе, диагностике, медикаментозном и хирургическом лечении жизнеопасных желудочковых аритмий у больных с ХСН, приводятся данные наиболее значимых многоцентровых клинических исследований последних десятилетий
Литература
Дощицын, В.Л. Внезапная аритмическая смерть и угрожающие аритмии/В.Л. Дощицын//Российский кардиологический журнал. -1999. -№1. -С. 46-51.
Дощицин, В.Л. Лечение аритмий сердца/В.Л. Дощицын. -М.:Медицина, 1993. -320 с.
Роль гуморальных факторов в патогенезе аритмий сердца/В.Д. Вахляев [и др.]//Российский медицинский журнал. -2000. -№ 2. -С. 54-57.
Amiodarone Early After Acute Myocardial Infarction//Eur. Heart J. -2000. -Vol.21. -P. 198-205.
Analysis of intracardiac electrograms showing monomorphic ventricular tachycardia in patients with implantable cardioverter-defibrillators/M. Saeed [et al.]//Am. J. Cardiol. -2000. -Mar. 1;85(5). -P.580-7.
AVID (Antiarrhythmics vs Implantable Defibrillators)//N. Engl. J. Med. -1997. -Vol.337. -P. 1576-1583.
AVID (B-Blocker Substudy)//J. Am. Coll. Cardiol. -1999. -Vol.34. -P.325-333.
Blocker Heart Attack Trial (BHAT) Group. A randomised trial of propranolol in patients with acute myocardial infarction. 1.Mortality results//JAMA. -1982. -Vol. 247. -P.1714-97.
Buxton, A.E. Current approaches to evaluation and management of patients with ventricular arrhythmias/A.E. Buxton, M.M. Kirk, G.T. Miehaud//Med. Health R. I. -2001. -Feb.84(2). -P. 58-62.
CASH (Cardiac Arrest Study: Hamburg)//Circulation. -2000. -Vol.102. -P.748-754.
CIDS (Canadian Implantable Defibrillator Study)//Circulation. -2000. -Vol.101. -P. 1297-1302.
D, L-Sotalol in patients with Ventricular Tachycardia and in Survivors of Cardiac Arrest//J. Am. Coll. Cardiol. -1 997. -Vol.30. -P.487-495.
Das, U.N. Beneficial effect(s) of n-3 fatty acids in cardiovascular diseases: but, why and how?/U.N. Das//Prostaglandins Leukot Essent Fatty Acids. -2001. -Jan. 64(1). -P.74.
De Sutter, J. Prevention of sudden death in patients with coronary artery disease: do lipid-lowering drugs play a role?/J. De Sutter, V. Firsovaite, R. Tavernier//Prev. Cardiol. -2002. -Fall. 5(4). -P. 177-82.
Demirovic, J. Epidemiology of sudden death: an overview/J. Demirovic, R.J. Myerburg//Progr. Cardiovasc. Dis. -1994. -Vol.37. -P.39-48.
DIAMOND (Danish Investigations of Arrhythmia and Mortality on Dofetilide)//Lancet. -2000. -Vol.356. -P.2052-2058.
Effect of beta-blockade on the premature ventricular beats/heart rate relation and heart rate variability in patients with coronary heart disease and severe ventricular arrhythmias/D. Acanfora [et al.]//Am. J. Ther. -2000. -Aug.7(4). -P.229-36.
Effect of beta-blocking therapy on outcome in the Multicenter UnSustained Tachycardia Trial (MUSTT)/K.E. Ellison [et al.]//Circulation. -2002. -Nov. 19;106(21). -P.2694-961.
Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators//N. Engl. J. Med. -1992. -Vol.327. -P. 685-91.
Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomized trials//Lancet. -1997. -Vol.350. -P. 1417-24.
Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group//N. Engl. J. Med. -1987. -Vol.316. -P.1429-35.
GABG-Patch (Coronary Artery Bypass Graft-Patch)//Circulation. -1999. -Vol.99. -P. 1416-1421.
Goldstein, S. Sudden cardiac death/S.Goldstein, A.Bayes-de-Luna, J. Gumdo-Soldevila. -Armonk: Futura, 1994. -343 p.
Halawa, B. Antiarrhythmic agents in the prevention of sudden cardiac death/B. Halawa//Pol. Merkuriusz. Lek. -1 999. -Mar. 6. -P. 117-20.
Hilleman, D.E. Role of antiarrhythmic therapy in patients at risk for sudden cardiac death: an evidence-based review/D.E. Hilleman, A.L. Bauman//Pharmacotherapy. -2001. -May 21(5). -P. 556-75.
Jespersen, C.M. Anti-ischemic intervention as prognosis improvement in patients with coronary artery disease, with special focus on verapamil/C.M. Jespersen//Am. J. Cardiol. -1996. -Jun.20; 77(16). -P.32-36.
Lanzmann-Petithory, D. Alpha-linolenic acid and cardiovascular diseases/D. Lanzmann-Petithory//J. Nutr. Health. Aging. -2001. -Vol.5(3). -P. 179-83.
Life potentials and arrhythmogesis/N. El-Sheriff [et al.]//PACE. -1985. -Vol.8. -P. 440.
Lipid lowering drugs and reccurences of life-threatening arrhythmias in high-risk patients/J. De Sutter [et al.]//J. Am. Coll. Cardiol. -2000. -Sep. 36(3). -P.766-72.
Long-term survival of patients with malignant ventricular arrhythmia triated with antyarrhythmicdrugs/T.B. Graboys [et al.]//Am. J. Cardiol. -1982. -Vol.50. -P.437.
MADIT(Multicentral Automatic defibrillator Implantation Trial)//Circulation. -1998. -Vol.97. -P.2129-2135.
Mortality and morbidity in patients receiving encainide and flecainide or placebo/D.S. Echt [at al.]//New Engl. J. Med. -1991. -Vol.324. -P.781-788.
MUSTT (Multicenter Unsustained Tachycardia Trial Investigation)//N. Engl. J. Med. -1999. -Vol.341. -P.1882-1890.
O'Callaghan, P.A. Evolving role of sotalol in the management of ventricular tachyarrhythmias/P.A. O'Callaghan, B.A. Mc Govern//Am. J. Cardiol. -1996. -Aug.29; 78(4A). -P.54-60.
Prevention of coronary heart disease in clinical practice: recomendations of the Task Forse of the European Society of Cardiology, European Aterosclerosis Society and European Society of Hypertension/К. Pyorala [et al.]//European Heart J. -1994. -Vol.l5. -P.l300-1331.
Prevention of Implantable Defibrillator or shocks by Treatment with Sotalol//N. Engl. J. Med. -1999. -Vol.340. -P.1855-1862.
Prognostic value of baseline electrophysiology studies in patients with sustained ventricular tachyarrhythmia: the Antiarrhythmics Versus Implantable Defibrillators (AVID) trial/M.A. Brodsky [et al.]//Am. Heart J. -2002. -Sep.144(3). -P.478-849.
Randomized trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction: EMIAT. Europian myocardial infarct amiodarone trial investigators/D.G. Julian [et al.]//Lancet. -1997. -Vol.349. -P.667-674.
Relation of ejection fraction and inducible ventricular tachycardia to mode of death in patients with coronary artery disease: an analysis of patients enrolled in the multicenter unsustained tachycardia trial/A.E. Buxton [et al.]//Circulation. -2002. -Nov.5;106(19). -P.2466-72.
Sorbera, C.A. Indications for implantable cardioverter defibrillator therapy/C.A. Sorbera, E.J. Cusack//Heart. Dis. -2002. -May-Jun. 4(3). -P. 166-70.
SWORD (Survival with Oral D-Sotalol)//J. Am.Coll. Cardiol. -1998. -Vol.81. -P.869-876.
The Cardiac Arrhythmia Supression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomised trial of arrhythmias supression after myocardial infarction//N. Engl. J. Med. -1989. -Vol.321. -P.406-410.
